PublicationSuperNovaDevelopment of Allogeneic Stem Cell-Based Platform for Delivery and Potentiation of Oncolytic VirotherapyNational Center for Biotechnology InformationDecember 13, 2022 Learn Morelaunch
PublicationNeuroNovaNeural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trialLancet OncologyAugust 22, 2021 Learn Morelaunch
PublicationSuperNovaEnhancement of the therapeutic effects of oncolytic vaccinia virus by using autologous and allogeneic cell-based delivery platforms.Journal of Clinical OncologyMay 25, 2020 Learn Morelaunch
PublicationNeuroNovaRationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patientsThe Journal of Translational MedicineMay 18, 2020 Learn Morelaunch
PublicationSuperNovaA cell-based platform to potentiate oncolytic virus: Potential approach for cancer therapies.Journal of Clinical OncologyFebruary 4, 2020 Learn Morelaunch
PublicationSuperNovaFirst-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cellsThe Journal of Translational MedicineAugust 19, 2019 Learn Morelaunch
PublicationNeuroNovaFirst-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cellsThe Journal of Translational MedicineAugust 19, 2019 Learn Morelaunch
PublicationSuperNovaDelivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriersThe Journal of Translational MedicineMarch 27, 2019 Learn Morelaunch
